Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

    More than monitoring whitepaper
    More than monitoring

    How modern monitoring paradigms impact CRA roles

    digital globe network with icons
    Meeting requirements for Joint Clinical Assessments

    A planning guide for health technology developers

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Best practices in global flow cytometry quality control and harmonisation

    5 March 2026. Register today.

    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    3 March 2026. Register today.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. Insights
  3. Blog
  4. Defining Key Performance Indicators and Governance

Defining Key Performance Indicators and Governance

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

  • 18 April 2024

A hallmark of high-performing partnerships is the establishment and maintenance of a governance model that aligns the interests of the sponsor and the CRO.

At a time when device manufacturers are under increasing pressure to improve pipeline productivity,  a critical area of focus involves the assessment of the key performance indicators (KPIs) that help bridge the gap between strategies and resultant operational achievements and efficiencies.

 

How KPIs can drive success — or failure

KPIs help organisations order priorities and guide the sponsor and CRO(s) to mutually valued outcomes. No matter what metrics are measured, the aim of any KPI is to bring about improvement(s), provide leading indicators of potential problems, and offer opportunities to course-correct. 

KPIs also drive two-way dialogue to inform changes to current operating practices to optimise the partnership’s long-term efficiency and effectiveness. A poorly chosen KPI, however, can lead to errant decision-making and undermine a program’s success. As an additional side effect, it also can have an effect on resource bandwidth since a great deal of time and energy could be spent collecting KPIs that aren’t actually moving the needle.

For example, if a CRO’s performance is judged by measuring recruitment success via the traditional metric of “time to first patient in,” a CRO is incentivised only to achieve a one-off performance. A substantial number of problems that may unexpectedly or unnecessarily expand a study’s duration or cost may be left out of the scope of a CRO’s responsibilities.

A KPI better aligned with a manufacturer’s success is “last patient out.” This places the responsibility on a CRO to resolve any issues that may threaten the overall recruitment speed and retention rate. Other KPIs that better align a CRO’s execution of a study with a manufacturer’s own success include time to database lock, monitoring quality, and even capital burn rate (for small or medium-sized manufacturers). 

However, if a KPI’s measurement does not trigger relevant corrective actions, its measurement generates little value. A contingency plan should be established in advance to respond to a KPI that crosses cautionary or critical thresholds. Such a plan should include steps that both partners have agreed upon to resolve potential roadblocks and help bring the KPI back on track.  

For example, in a trial in which enrolment is expected to be challenging, when the enrolment rate at a few key sites falls behind, a plan should be outlined specifying how the CRO will investigate the root cause of the delay and address the issue with those sites.

Furthermore, the plan should specify a threshold at which the manufacturer may take more significant actions, such as to approve the addition of a new site to the trial. Setting expectations for adverse scenarios in this manner strengthens a partnership and the resulting outcomes.

 

Win-win for sponsor and CRO

Manufacturers can benefit from provisions that are set up for CROs to share both risk and reward. Missing KPIs could incur progressive penalties, including the inability to bid on subsequent projects, whereas a certain level of over performance could generate progressive rewards, such as bonus payments or the ability to earn back previously incurred service credits. Here, manufacturers and CROs are incentivized to engage in risk-sharing activities, in which CROs are encouraged to draw on the full range of capabilities that may not otherwise be leveraged or visible.

In addition to considering risk based pricing/contracting models, partnerships should put in place provisions for continuous improvements to drive value throughout and beyond the life of the partnership. This approach sets year-on-year targets for incremental efficiency improvements. Such targets promote the integration of the manufacturer and CRO’s staff and processes to achieve the most efficient collaboration.  

Maximising efficiencies will likely require the CRO to adapt processes and operational structures over time to best interface with a manufacturer. Likewise, manufacturers may find that they can achieve enhanced productivity by adapting their organisation(s) to best interface with the CRO partner. In other words, if a manufacturer knows that its long-term strategy and growth is dependent on a significant outsourcing strategy, organisational structure and redesign should be considered. Since these adaptations often extend beyond a single trial, continuous improvement functions work best when governed by a dedicated governance committee, including the presence of process improvement leaders at both the CRO and manufacturer who are empowered to drive change.

For all levels of leadership, the governance and measurement reporting structure driving the overall partnership strategy should specify the degree of transparency into ongoing outsourced trial activities. A CRO should be able to provide a live view of a trial’s progress, including enrolment numbers, quality metrics, and adherence to milestones. More sophisticated CROs provide a single web portal that allows for on-demand reporting and analysis of real-time trial operational data, as well as communication with relevant staff.

 

The metrics that matter

While the metrics that matter to each manufacturer vary, ICON has found that inclusion of metrics across four categories — finance, quality, operations, and relationship health — provides the most robust representation of a partnership’s overall performance. These partnership-level metrics should not be as granular as the sub-layer of potentially hundreds of operational metrics that detail an individual trial’s progression, but should still provide leading indicators of potential problems and thus opportunities to course correct. 

When selecting KPIs, it is important to be specific. For example, a relationship health KPI for “staff retention” should specify whether turnover is calculated based on staff retained on a specific project, programme, or at the CRO itself. At the partnership level, sample KPIs include:  

Finance 

  • Turnaround times for work order development 
  • Payments to sites 
  • Revenue burn rate 
  • Plan to actuals for study 

Quality 

  • Audit findings 
  • Monitoring turnaround time for closing out action items 
  • Compliance rates 

Operations 

  • Protocol amendments 
  • Cycle times 
  • Enrolment rates 

Relationship health 

  • Quarterly two-way surveys (or one-on-one interviews) to measure the satisfaction of people working on the alliance, including opinions on training, on boarding, and operating processes 
  • Staff retention rate

 

Conclusion

Well-defined KPIs have the potential to drive additional value to the outsourcing partnership. They can be used to help organisations become more efficient and provide a useful measure regarding the effectiveness of the CRO/sponsor relationship. With appropriate governance structures and metrics in place, KPIs become a major driver of constant improvement and innovation in outsourcing relationships.

In this section
In this section
  • Digital Disruption
    • Clinical strategies to optimise SaMD for treating mental health
    • Digital Disruption: Surveying the industry's evolving landscape
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
      • Using AI for site ID and selection
      • Applying AI to manage the risks and costs of postmarketing requirements
      • Integrating AI into Clinical Research: How AI is Enhancing Clinical Development
    • Clinical trial data anonymisation and data sharing
    • Clinical Trial Tokenisation
    • Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
    • mHealth wearables
      • Cybersecurity
      • Digital Endpoints
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
    • The triad of trust: Navigating real-world healthcare data integration
    • Decoding AI in software as a medical device (SaMD)
    • Software as a medical device (SaMD)
      • Developing AI in SaMD
  • Patient Centricity
    • Accelerating clinical development through DHTs
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Representation and inclusion in clinical trials
      • Diversity and inclusion in clinical trials whitepaper
    • Exploring the patient perspective from different angles
    • Patient safety and pharmacovigilance
      • A guide to safety data migrations
      • Taking safety reporting to the next level with automation
      • Outsourced Pharmacovigilance Affiliate Solution
      • The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
      • Sponsor and CRO pharmacovigilance and safety alliances
      • Understanding the Periodic Benefit-Risk Evaluation Report
    • Patient voice survey
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
    • Using longitudinal qualitative research to capture the patient voice
    • Prioritising patient-centred research for regulatory approval
  • Regulatory Intelligence
    • Accelerating access
    • Meeting requirements for Joint Clinical Assessments
    • Navigating the regulatory landscape in the US and Japan:
    • Preparing for ICH GCP E6(R3) implementation
    • An innovative approach to rare disease clinical development
    • EU Clinical Trials Regulation
      • EMA guideline on computerised systems and electronic data in clinical trials
      • EU CTR Whitepaper
    • Using innovative tools and lean writing processes to accelerate regulatory document writing
    • Current overview of data sharing within clinical trial transparency
    • Global Agency Meetings: A collaborative approach to drug development
    • Keeping the end in mind: key considerations for creating plain language summaries
    • Navigating orphan drug development from early phase to marketing authorisation
    • Procedural and regulatory know-how for China biotechs in the EU
    • RACE for Children Act
    • Early engagement and regulatory considerations for biotech
    • Regulatory Intelligence Newsletter
    • Requirements & strategy considerations within clinical trial transparency
    • Spotlight on regulatory reforms in China
    • Demystifying EU CTR, MDR and IVDR
    • Transfer of marketing authorisation
    • Exploring FDA guidance for modern Data Monitoring Committees
    • Streamlining dossier preparation
  • Therapeutics insights
    • Endocrine and Metabolic Disorders
    • Cardiovascular
      • Mitigating the impact of COVID-19 on cardiovascular trials
    • Cell and Gene Therapies
      • Approaching the CAR T-cell therapy horizon
      • Cell and Gene ebook
      • Long-term follow-up studies of cell and gene therapies
      • Mainstreaming Cell & Gene Therapies
    • Central Nervous System
      • A mind for digital therapeutics
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
      • Key Considerations in Chronic Pain Clinical Trials
      • ICON survey report: CNS therapeutic development
    • Glycomics
    • Infectious Diseases
      • Antimicrobial Resistance
      • Considerations for strengthening vaccine development
      • COVID-19 vaccine trials
      • COVID-19 vaccines: Post-authorisation safety surveillance
      • HIV
      • The value of dynamic transmission models
    • NASH
      • The voice of NASH investigators
    • Obesity
      • Addressing obesity's impact across the disease spectrum
      • Trends and challenges in obesity research and clinical trials
      • Obesity and beyond: embracing multi-indication potential during clinical development
      • Survey report: How today’s obesity developers are navigating a multi-indication landscape
    • Oncology
      • ICON survey report: Innovation in Oncology
      • De-risking clinical development of precision medicines in oncology
      • Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
      • The future of oncology biosimilars
    • Paediatrics
      • Paediatric Risk Assessment Map
    • Respiratory
    • Rare and orphan diseases
      • Advanced therapies for rare diseases
      • Cross-border enrollment of rare disease patients
      • Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
      • Diversity, equity and inclusion in rare disease clinical trials
      • Identify and mitigate risks to rare disease clinical programmes
      • Leveraging historical data for use in rare disease trials
      • Natural history studies to improve drug development in rare diseases
      • Patient Centricity in Orphan Drug Development
      • The key to remarkable rare disease registries
      • Therapeutic spotlight: Precision medicine considerations in rare diseases
  • Transforming Trials
    • Accelerating biotech innovation from discovery to commercialisation
    • Demystifying the Systematic Literature Reviews
    • Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
    • From bottlenecks to breakthroughs
    • Linguistic validation of Clinical Outcomes Assessments
    • More than monitoring
    • Optimising biotech funding
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • Best practices to increase engagement with medical and scientific poster content
    • Decentralised clinical trials
      • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
      • Decentralised and Hybrid clinical trials
      • Practical considerations in transitioning to hybrid or decentralised clinical trials
      • Navigating the regulatory labyrinth of technology in decentralised clinical trials
    • eCOA implementation
    • Blended solutions insights
      • Clinical trials in Japan: An enterprise growth and management strategy
      • How investments in supply of CRAs is better than competing with the demand for CRAs
      • The evolution of FSP: not just for large pharma
      • Embracing a blended operating model
      • Observations in outsourcing: Survey results show a blended future
    • Implications of COVID-19 on statistical design and analyses of clinical studies
    • Improving pharma R&D efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Innovation in Clinical Trial Methodologies
    • Partnership insights
      • Exploring partnership culture and its impact on outsourcing and operational strategy
    • Risk Based Quality Management
    • Transforming the R&D Model to Sustain Growth
  • Value Based Healthcare
    • Strategies for commercialising oncology treatments for young adults
    • US payers and PROs
    • Accelerated early clinical manufacturing
    • Cardiovascular Medical Devices
    • CMS Part D Price Negotiations: Is your drug on the list?
    • COVID-19 navigating global market access
    • Ensuring scientific rigor in external control arms
    • Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
    • Health technology assessment
    • Perspectives from US payers
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Medical communications in early phase product development
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • Survey results: How to engage healthcare decision-makers
    • The affordability hurdle for gene therapies
    • The Role of ICER as an HTA Organisation
    • Integrating openness and precision for competitive advantage
  • Blog
  • Videos
  • Webinar Channel

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence